- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
NEW YORK ( TheStreet) -- Gilead (Nasdaq: GILD) hit a new 52-week high Friday as it is currently trading at $74.14, above its previous 52-week high of $73.20 with 2.6 million shares traded as of 9:50 a.m. ET. Average volume has been 8.2 million shares over the past 30 days. Gilead has a market cap of $108.99 billion and is part of the health care sector and drugs industry. Shares are up 93.5% year to date as of the close of trading on Thursday. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. The company has a P/E ratio of 39.1, above the S&P 500 P/E ratio of 17.7.